These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2137 related articles for article (PubMed ID: 27192565)
1. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Anderson AC; Joller N; Kuchroo VK Immunity; 2016 May; 44(5):989-1004. PubMed ID: 27192565 [TBL] [Abstract][Full Text] [Related]
2. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study. Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173 [TBL] [Abstract][Full Text] [Related]
3. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831 [TBL] [Abstract][Full Text] [Related]
4. Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute Herrmann M; Schulte S; Wildner NH; Wittner M; Brehm TT; Ramharter M; Woost R; Lohse AW; Jacobs T; Schulze Zur Wiesch J Front Immunol; 2020; 11():1870. PubMed ID: 32983106 [TBL] [Abstract][Full Text] [Related]
5. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905 [TBL] [Abstract][Full Text] [Related]
6. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Dougall WC; Kurtulus S; Smyth MJ; Anderson AC Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695 [TBL] [Abstract][Full Text] [Related]
7. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer. Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406 [TBL] [Abstract][Full Text] [Related]
8. Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study. Jin S; Shang Z; Wang W; Gu C; Wei Y; Zhu Y; Yang C; Zhang T; Zhu Y; Zhu Y; Wu J; Ye D J Immunother; 2023 May; 46(4):154-159. PubMed ID: 37017991 [TBL] [Abstract][Full Text] [Related]
9. Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis. Lavon I; Heli C; Brill L; Charbit H; Vaknin-Dembinsky A Front Immunol; 2019; 10():835. PubMed ID: 31134049 [No Abstract] [Full Text] [Related]
10. Increased Expression of Multiple Co-Inhibitory Molecules on Malaria-Induced CD8 Brandi J; Riehn M; Hadjilaou A; Jacobs T Front Immunol; 2022; 13():878320. PubMed ID: 35874786 [TBL] [Abstract][Full Text] [Related]
11. Expression of immune checkpoints in T cells of esophageal cancer patients. Xie J; Wang J; Cheng Sh; Zheng L; Ji F; Yang L; Zhang Y; Ji H Oncotarget; 2016 Sep; 7(39):63669-63678. PubMed ID: 27577071 [TBL] [Abstract][Full Text] [Related]
12. Not All Immune Checkpoints Are Created Equal. De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P Front Immunol; 2018; 9():1909. PubMed ID: 30233564 [TBL] [Abstract][Full Text] [Related]
13. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. Thommen DS; Schreiner J; Müller P; Herzig P; Roller A; Belousov A; Umana P; Pisa P; Klein C; Bacac M; Fischer OS; Moersig W; Savic Prince S; Levitsky V; Karanikas V; Lardinois D; Zippelius A Cancer Immunol Res; 2015 Dec; 3(12):1344-55. PubMed ID: 26253731 [TBL] [Abstract][Full Text] [Related]
14. On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment. Tundo GR; Sbardella D; Lacal PM; Graziani G; Marini S Chemotherapy; 2019; 64(2):62-80. PubMed ID: 31387102 [TBL] [Abstract][Full Text] [Related]
15. Check point inhibitors as therapies for infectious diseases. Cox MA; Nechanitzky R; Mak TW Curr Opin Immunol; 2017 Oct; 48():61-67. PubMed ID: 28865357 [TBL] [Abstract][Full Text] [Related]
16. Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis. Yu Y; Chen Z; Wang Y; Li Y; Lu J; Cui L; Yu Z; Ding Y; Guo C; Zhang X; Shi Y Int Immunopharmacol; 2021 Jul; 96():107722. PubMed ID: 33965878 [TBL] [Abstract][Full Text] [Related]
17. [The expression and prognostic value of PD-1, TIM-3, LAG-3 and BTLA in extranodal NK/T cell lymphoma]. Nie L; Liu XY; Ma RJ; Yuan XL; Jiang L; Yang J; Hu AX; Li Z; Zhu ZM Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):598-602. PubMed ID: 34455749 [No Abstract] [Full Text] [Related]
19. LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. Joller N; Anderson AC; Kuchroo VK Immunity; 2024 Feb; 57(2):206-222. PubMed ID: 38354701 [TBL] [Abstract][Full Text] [Related]
20. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Sasidharan Nair V; Toor SM; Taha RZ; Shaath H; Elkord E Clin Epigenetics; 2018 Aug; 10(1):104. PubMed ID: 30081950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]